- Home
- CKPT vs MIN Comparison
CKPT vs MIN Comparison
Compare CKPT & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- MIN
- Stock Information
- Founded
- CKPT 2014
- MIN 1988
- Country
- CKPT United States
- MIN United States
- Employees
- CKPT N/A
- MIN N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- MIN Trusts Except Educational Religious and Charitable
- Sector
- CKPT Health Care
- MIN Finance
- Exchange
- CKPT Nasdaq
- MIN Nasdaq
- Market Cap
- CKPT 361.1M
- MIN 304.4M
- IPO Year
- CKPT 2017
- MIN N/A
- Fundamental
- Price
- CKPT $4.26
- MIN $2.68
- Analyst Decision
- CKPT Buy
- MIN
- Analyst Count
- CKPT 3
- MIN 0
- Target Price
- CKPT $4.33
- MIN N/A
- AVG Volume (30 Days)
- CKPT 2.1M
- MIN 331.0K
- Earning Date
- CKPT 05-13-2025
- MIN 01-01-0001
- Dividend Yield
- CKPT N/A
- MIN 7.31%
- EPS Growth
- CKPT N/A
- MIN N/A
- EPS
- CKPT N/A
- MIN 0.08
- Revenue
- CKPT $41,000.00
- MIN N/A
- Revenue This Year
- CKPT $102,182.93
- MIN N/A
- Revenue Next Year
- CKPT $351.71
- MIN N/A
- P/E Ratio
- CKPT N/A
- MIN $33.38
- Revenue Growth
- CKPT N/A
- MIN N/A
- 52 Week Low
- CKPT $1.80
- MIN $2.52
- 52 Week High
- CKPT $4.50
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- CKPT 80.26
- MIN 51.79
- Support Level
- CKPT $4.14
- MIN $2.64
- Resistance Level
- CKPT $4.20
- MIN $2.68
- Average True Range (ATR)
- CKPT 0.03
- MIN 0.03
- MACD
- CKPT -0.00
- MIN -0.00
- Stochastic Oscillator
- CKPT 85.71
- MIN 66.67
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.